VF00102 / Vitrogro as a pain killer

I am still trying to give a sense to this costly nightmare.

There is a very important point still to be addressed and is relative to the 44 +157 patients trials (the previous EU one and the current US trial).

One of the endpoint was the pain reduction.

We were saying in both that patients were responding to a less pain/good mood response applying the product.
Is this correct?

If positive, we could think about our product as a pain killer during long and strenuous wound treatments. So we would gave a complime tary product to be vombI ed wIth standard care.

Isn't it?
If positive we still have an open road as a pain killer, that make our product still is a valuable asset.
To apply for US approval is simpler as we have already data to proof our claim.

This claim is based on both the trials. In Europe patients were happy to receive the treatment and responded about less pain.

As a pain killer during world treatment t we can apply this topical medication on a worldwide basis.

Could FTT apply as a pain killer to the Australian Health Authority. Any local approval would build value on a step by step basis.